Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-09-07 |
Cell Therapy Catapult (UK) TrakCel (UK) |
needle-to-needle supply chain management platform |
|
collaboration |
Technology - Services |
Collaboration agreement |
2017-09-07 |
Eli Lilly (USA - IN) |
|
|
restructuring |
|
Restructuring |
2017-09-07 |
Abivax (France) Evotec (Germany) |
small molecules for the treatment of multiple serious viral infectious diseases |
viral infectious diseases |
development |
Infectious diseases |
Development agreement |
2017-09-07 |
Iovance Biotherapeutics (US - CA) The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) (USA - OH) |
tumor-infiltrating lymphocyte (TIL), marrow-infiltrating lymphocyte (MIL) and peripheral blood-associated lymphocyte technologies |
hematologic malignancies including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). |
research - R&D |
Cancer - Oncology |
Research agreement |
2017-09-06 |
OSE Immunotherapeutics (France) GERCOR (France) |
Tedopi® |
locally advanced or metastatic pancreatic cancer |
clinical research |
Cancer - Oncology - Rare diseases |
Clinical research agreement |
2017-09-06 |
Bioverativ (USA - MA) Bicycle Therapeutics (USA - MA) |
Bicycles |
hemophilia, sickle cell disease |
research - development - R&D |
Rare diseases - Genetic diseases - Hematological diseases |
Research agreement |
2017-09-06 |
BioNTech (Germany) Cellscript (USA - WI) |
nucleoside-modified messenger RNA (mRNA) |
|
licensing |
Technology - Services |
Licensing agreement |
2017-09-05 |
Boehringer Ingelheim (Germany) Inventiva (France) |
new medicines for the treatment of idiopathic pulmonary fibrosis |
idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases |
research - R&D - licensing |
Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases |
Exercise of an option agreement |
2017-09-05 |
Portola Pharmaceuticals (USA - CA) Lonza (Switzerland) |
AndexXa®(US)/ IndexXa™ (EU) |
|
production - manufacturing |
|
Production agreement |
2017-09-05 |
TiGenix (Belgium) |
manufacturing facility in Madrid |
|
validation of a production plant |
Autoimmune diseases - Inflammatory diseases |
Validation of a production plant |
2017-09-05 |
Retrotope (USA - CA) National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) (USA) NGLY1.org (USA - UT) |
small molecule therapeutics for NGLY1 deficiency |
NGLY1 deficiency |
research |
Rare diseases - Genetic diseases - Neurodevelopmental diseases |
Research agreement |
2017-09-04 |
Novartis (Switzerland) |
|
|
resignation - nomination |
|
Nomination |
2017-09-04 |
Abbvie (USA - IL) Inventiva (France) |
ROR-gamma inverse agonists |
|
research - development |
|
Research agreement |
2017-09-04 |
Eyevensys (France) |
chief medical officer |
|
nomination |
Ophtalmological diseases |
Nomination |
2017-09-01 |
Oncurious (Belgium) VIB (Belgium) |
immuno-oncology assets |
|
product acquisition |
Cancer - Oncology |
Product acquisition |
2017-08-31 |
Macrogenics (USA - MD) Janssen Biotech, a J&J company (USA - NJ) |
MGD015 (JNJ-9383) |
hematological cancers, solid tumors |
|
Cancer - Oncology |
Licensing agreement |
2017-08-31 |
Nabriva Therapeutics (Ireland) |
chief medical officer |
|
resignation |
Infectious diseases |
Resignation |
2017-08-31 |
BeiGene (China) Celgene (USA - NJ) |
BGB-A317, Celgene's approved therapies in China (Abraxane®, Revlimid®, Vidaza®) and pipeline agent CC-122 |
solid tumors |
development - commercialisation |
Cancer - Oncology |
Development agreement |
2017-08-30 |
Roche (Switzerland) Pharmstandard (Russia) |
Gaziva® (obinutuzumab) |
|
bioproduction - manufacturing |
Cancer - Oncology |
Production agreement |
2017-08-29 |
Boston Pharmaceuticals (USA - MA) Daiichi Sankyo (Japan) |
DS-5010 |
|
licensing |
Cancer - Oncology |
Licensing agreement |